2005 News Archive

2005 SCDAA News Archive

  • SCDAA Responds Favorably to Positive Review of Exjade by FDA Advisory Committees (10-03-05)
    The Sickle Cell Disease Association of America (SCDAA) is excited by the news that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) has given a positive review of ExjadeŽ (deferasirox) for once-daily oral treatment of adults and children with chronic iron overload due to blood transfusions.

  • A word from SCDAA on Hurricane Katrina (09-02-05)
    The President, Chairman, National Board of Directors and staff of Sickle Cell Disease Association of America, Inc., express their heartfelt sympathies and concerns to all those affected by the recent devastation caused by hurricane Katrina.

  • An Evening of Jazz (06-21-05)
    SCDAA and Capital Jazz present "An Evening of Jazz" featuring Kim Waters on Friday, Sept. 9.

  • SCDAA Statement on ExjadeŽ (deferasirox) (05-03-05)
    Novartis files regulatory submissions for ExjadeŽ (deferasirox), the first and only once-daily oral iron chelator for the treatment of chronic iron overload due to blood transfusions.

  • ACTION ALERT (03-04-05)
    SCDAA needs your support in securing funding for the programs established by the Sickle Cell Treatment Act

See the archived news items:
2009 News Archive2008 News Archive2007 News Archive2005 News Archive2004 News ArchivePrevious News Archive


Copyright © 2005 Sickle Cell Disease Association of America, Inc.
231 East Baltimore Street • Suite 800 • Baltimore, Maryland 21202
410.528.1555 Office • 410.528.1495 Fax • 800.421.8453 Toll Free
E-Mail: scdaa@sicklecelldisease.org